GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocon Ltd (NSE:BIOCON) » Definitions » Float Percentage Of Total Shares Outstanding

Biocon (NSE:BIOCON) Float Percentage Of Total Shares Outstanding : 0.00% (As of Jun. 06, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Biocon Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Biocon's float shares is 0.00 Mil. Biocon's total shares outstanding is 1,196.80 Mil. Biocon's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Biocon's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Biocon's Institutional Ownership is 13.03%.


Biocon Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Biocon's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/1,196.80
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biocon (NSE:BIOCON) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocon Ltd (NSE:BIOCON) » Definitions » Float Percentage Of Total Shares Outstanding
Traded in Other Exchanges
Address
20th KM, Hosur Road, Electronics City, Bengaluru, KA, IND, 560 100
Biocon Ltd is a biopharmaceutical company that develops biotechnology therapies for diseases. The company is focused on developing, manufacturing, and supplying novel and biosimilar pharmaceuticals for diabetes, cancer, and autoimmune conditions. Biocon has four reportable segments: Generics, Biosimilars, Novel Biologics (Novels), and Research services (Research). The company provides integrated contract research and manufacturing services to pharmaceutical and biotechnology companies through its subsidiary Syngene.

Biocon (NSE:BIOCON) Headlines

No Headlines